Please assess the completion status of the following clinical trial:

Trial Title: Cabergoline in Nonfunctioning Pituitary Adenomas

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* presence of pituitary tumor rest at 6 months after neurosurgery~* absence of previous hormonal pituitary hypersecretion~* absence of previous radiotherapy and/or radiosurgery~* Histopathological exam showing pituitary adenoma~Exclusion Criteria:~* ACTH immunoexpression at histopathological exam~* presence of previous radiotherapy and/or radio surgery~* psychotic psychiatric disease~* moderate or severe alterations in cardiac valves

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Study Group (Type: EXPERIMENTAL): This group received cabergoline, in a total week dose of 3.5 mg, starting 6 months after transphenoidal surgical approach with evidence of tumoral rest in MRI and pituitary adenoma hystopathological confirmation.
- Control Group (Type: NO_INTERVENTION): This group was followed, with clinical visits in same frequency of study group, but without intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).